Image-based profiling decodes complex cellular states for high-impact biological and therapeutic applications, yet a large, public reference dataset of chemical perturbations has been lacking. We present Cell Painting images and 1.53 billion single-cell profiles for 115,796 compounds in human osteosarcoma cells, generated by the Joint Undertaking for Morphological Profiling (JUMP)-Cell Painting Consortium of 18 industry and non-profit partners. Despite technical variability across 12 data-generating laboratories, more than 15% of compounds show statistically significant phenotypic activity, reproducibility drops only 34% versus single-laboratory data, and compounds sharing biological targets often show similar image-based profiles. JUMP establishes a validated public reference resource that brings image-based profiling on par with genomics and transcriptomics. The dataset, shared alongside previously released genetic perturbation data in the Cell Painting Gallery, is a powerful predictive engine for the impact, mechanism, targets and activities of compounds, fundamentally accelerating chemical and cell biology and early-stage drug development.
Biosynthesis of glycosylphosphatidylinositol (GPI) is required for anchoring proteins to the plasma membrane, and is essential for the integrity of the fungal cell wall. Here, we use a reporter gene-based screen in Saccharomyces cerevisiae for the discovery of antifungal inhibitors of GPI-anchoring of proteins, and identify the oligocyclopropyl-containing natural product jawsamycin (FR-900848) as a potent hit. The compound targets the catalytic subunit Spt14 (also referred to as Gpi3) of the fungal UDP-glycosyltransferase, the first step in GPI biosynthesis, with good selectivity over the human functional homolog PIG-A. Jawsamycin displays antifungal activity in vitro against several pathogenic fungi including Mucorales, and in vivo in a mouse model of invasive pulmonary mucormycosis due to Rhyzopus delemar infection. Our results provide a starting point for the development of Spt14 inhibitors for treatment of invasive fungal infections.